17 citations
,
November 2021 in “Journal of Cosmetic Dermatology” This review discusses treatment options for androgenetic alopecia, highlighting the need for personalized, evidence-based approaches but reports no new clinical results.
July 2021 in “Journal of reports in pharmaceutical sciences” This study evaluated a new aqueous-based nanosuspension of minoxidil for treating androgenetic alopecia and reported it was as effective as the commercial product but had better safety and tolerability, potentially improving patient compliance.
April 2020 in “Dermatology and therapy” In this study, the novel 5% minoxidil formulation significantly increased scalp hydration and decreased redness in Indian men with androgenetic alopecia compared to alcohol-based formulations.
22 citations
,
March 2020 in “Cosmetics” This review discusses the potential of nanotechnology-based formulations for delivering topical minoxidil to improve hair loss treatment outcomes and reports no new clinical results, urging further research into their benefits and safety considerations.
117 citations
,
August 2019 in “Drug Design Development and Therapy” This review article provides an updated overview of the pharmacology, mechanism of action, clinical efficacy, and adverse events associated with topical minoxidil, a widely used treatment for androgenetic alopecia and other hair loss conditions, while noting that its exact mechanism is still not fully understood.
178 citations
,
April 2017 in “Journal of The American Academy of Dermatology” This systematic review and meta-analysis found that minoxidil, finasteride, and low-level laser light therapy significantly improve hair growth in men with androgenetic alopecia, while minoxidil is also effective for women, compared to placebo.
4 citations
,
January 2016 in “Acta dermatovenerologica Alpina, Pannonica et Adriatica (Tiskana izd.)” This study evaluated the efficacy and safety of a 5% minoxidil topical foam without propylene glycol in men with androgenic alopecia.
100 citations
,
June 2011 in “Journal of The American Academy of Dermatology” This study found that a once-daily 5% minoxidil topical foam is as effective as a twice-daily 2% minoxidil topical solution for hair growth in women with androgenetic alopecia, with fewer side effects and greater styling convenience.
51 citations
,
May 2010 in “Journal of Drug Targeting” This study found that Transcutol-containing vesicles improved the delivery of minoxidil to deeper skin layers in vitro but did not facilitate its permeation through the skin.
142 citations
,
August 2007 in “Journal of The American Academy of Dermatology” This study found that a new 5% minoxidil foam formulation significantly increased hair counts and improved hair loss condition in men with androgenetic alopecia over 16 weeks compared to placebo.
10 citations
,
May 2007 in “PubMed” This study found that 1% topical minoxidil significantly increased hair count and improved hair growth perception among Japanese women with androgenetic alopecia compared to placebo.
219 citations
,
March 2004 in “Journal of The American Academy of Dermatology” In this 48-week trial, 5% topical minoxidil was more effective than both 2% minoxidil and placebo in promoting hair growth in women with female pattern hair loss, with notable improvements in nonvellus hair count and hair growth assessments.
2 citations
,
March 2004 in “Journal of the American Academy of Dermatology” Minoxidil 5% solution quickly improves hair growth and density with minimal side effects.
57 citations
,
August 2003 in “British Journal of Dermatology” This study found that daily use of 1% pyrithione zinc shampoo modestly improved hair growth over 26 weeks, although these effects were less than those of 5% minoxidil.
269 citations
,
August 2002 in “Journal of The American Academy of Dermatology” This study found that 5% topical minoxidil significantly increased hair regrowth and improved psychosocial perceptions of hair loss in men with androgenetic alopecia compared to 2% topical minoxidil and placebo over 48 weeks.
